Key clinical point: Interleukin-1 alpha shows early potential as a novel therapeutic target in atopic dermatitis.
Major finding: Scores on the Eczema Area and Severity Index dropped by a mean of 65% from baseline at week 4 of bermekimab at 400 mg/week, and by 80% at week 8.
Study details: This phase 2, dose-ranging study included 28 adults with atopic dermatitis placed on 400 mg of bermekimab given subcutaneously once a week for 8 weeks.
Disclosures: The presenter reported receiving research funding from and serving as a consultant to XBiotech, the study sponsor.
Gottlieb AB. EADV 2019, late breaker.